[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565830":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":20,"id":44,"slug":20,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":20,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":20,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":20,"overallStatus":62,"whyStopped":20,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"ProgenaBiome","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"PD patients","This is an open-label clinical trial to evaluate the Safety of fecal microbiota transplant following a 10 day treatment with Vancomycin in adult subjects with Parkinson's disease.",[12],"Combination Product: Fecal Microbiota Transplant",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":18},"COMBINATION_PRODUCT","Fecal Microbiota Transplant",[9],[19],"Vancomycin",null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Alex Lopez","CONTACT","8053390549","alex@progenabiome.com",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"Sabine Hazan","Ventura","California","93003","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-119.29317,34.27834,{"lat":39,"lon":38},{"type":42,"investigatorFullName":29,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100565830",false,"NCT06647277","Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease","An Open-Label Phase I Clinical Trial of Vancomycin Followed by Fecal Microbiota Transplant for the Treatment of Parkinson's Disease","Inclusion Criteria:\n\n* Individuals diagnosed with PD\n\nExclusion Criteria:\n\n* Non-PD individuals","ALL","18 Years","85 Years",{"count":54,"type":55},10,"ESTIMATED","INTERVENTIONAL",[58],"PHASE1","FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.",[61],"Parkinson Disease","NOT_YET_RECRUITING","2025-06-23",{"date":65,"type":66},"2025-06-26","ACTUAL",{"date":68,"type":55},"2026-07",{"date":70,"type":55},"2027-12",{"name":5,"class":6},1]